VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ALGS
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ALGSAligos Therapeutics, Inc.
$2.10$13M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksALGSBalance Sheet

Aligos Therapeutics, Inc. (ALGS) Balance Sheet

8Y historyFree accessUpdated daily

The company maintains a conservative debt-to-equity ratio of 0.14 as of 2026Q1, though this is overshadowed by a massive cumulative retained earnings deficit of $665.2M.

Income StatementBalance SheetCash FlowRatios

ALGS Balance Sheet

Annual statement

ALGS Balance Sheet

Aligos Therapeutics, Inc. (ALGS) balance sheet — 8-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18
Total Current Assets34.68M82.86M62.14M141.08M133.54M204.42M250.02M120.23M92.37M
Cash & Short-Term Investments31.09M77.84M56.94M135.7M125.83M190.73M243.51M117.66M90.85M
Cash Only31.09M18.3M37M135.7M81.35M186.82M220.38M69.56M24.04M
Short-Term Investments059.54M19.94M044.48M3.92M23.13M48.1M66.82M
Accounts Receivable000000000
Days Sales Outstanding75.34--------
Inventory000000000
Days Inventory Outstanding---------
Other Current Assets3.59M5.02M5.2M5.38M7.72M13.69M6.5M2.56M1.52M
Total Non-Current Assets12.51M5.67M7.95M10.44M13.15M30.95M15.29M26.29M15.36M
Property, Plant & Equipment12.24M4.96M7.33M9.82M12.51M14.97M14.91M16.09M15.18M
Fixed Asset Turnover5.43x0.44x0.54x1.58x1.11x0.29x---
Goodwill000000000
Intangible Assets000000000
Long-Term Investments0000015.11M010.02M0
Other Non-Current Assets268K715K627K625K634K866K377K188K178K
Total Assets47.19M88.53M70.09M151.53M146.69M235.37M265.3M146.52M107.73M
Asset Turnover0.50x0.02x0.06x0.10x0.09x0.02x---
Asset Growth %-137.13%26.31%-53.74%3.3%-37.68%-11.28%81.07%36.01%-
Total Current Liabilities19.6M21.23M21.74M23.91M33.13M38.96M30.27M13.82M7.49M
Accounts Payable3.21M3.98M2.57M2.52M4.74M3.02M3.31M3.77M2.98M
Days Payables Outstanding7.55K1.56K----363.68598.07841.68
Short-Term Debt000000000
Deferred Revenue (Current)00151K1.31M9.21M7.64M7.89M03.18M
Other Current Liabilities07.46M6.39M6.67M6.36M6.61M7.84M3.96M272K
Current Ratio1.77x3.90x2.86x5.90x4.03x5.25x8.26x8.70x12.33x
Quick Ratio1.77x3.90x2.86x5.90x4.03x5.25x8.26x8.70x12.33x
Cash Conversion Cycle-7.48K--------
Total Non-Current Liabilities16.28M13.76M79.09M35.54M9.66M11.68M14.99M197.59M113.99M
Long-Term Debt000000000
Capital Lease Obligations13.13M1.52M4.92M7.9M9.43M11.55M10.5M11.88M12.61M
Deferred Tax Liabilities1.05M01.76M000000
Other Non-Current Liabilities5.62M12.23M72.41M27.64M0133K379K185.71M101.38M
Total Liabilities35.88M34.99M99.07M59.45M42.79M50.64M45.26M211.41M121.48M
Total Debt11.9M5.25M8.38M11.14M12.57M14.46M13.01M14.33M13.86M
Net Debt-19.19M-13.05M-28.62M-124.57M-68.77M-172.36M-207.38M-55.23M-10.17M
Debt / Equity1.05x0.10x-0.12x0.12x0.08x0.06x--
Debt / EBITDA-0.17x--------
Net Debt / EBITDA0.27x--------
Interest Coverage-------10.28x--
Total Equity11.31M53.55M-28.97M92.08M103.9M184.73M220.04M-64.89M-13.75M
Equity Growth %59.15%284.81%-131.47%-11.38%-43.76%-16.05%439.09%-372%-
Book Value per Share1.085.42-4.623.702.434.646.44-2.96-0.65
Total Shareholders' Equity11.31M53.55M-28.97M92.08M103.9M184.73M220.04M-64.89M-13.75M
Common Stock9K9K8K7K4K4K4K03K
Retained Earnings-688.61M-642.2M-618.01M-486.8M-399.12M-303.07M-174.74M-66.2M-13.93M
Treasury Stock000000000
Accumulated OCI437K468K451K545K401K452K-188K-115K3K
Minority Interest000000000

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Imminent capital dilution risk

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Asset Base Erosion Signals Distress

As reported in financial statements, total assets have declined from $151.5M in 2023Q4 to $64.6M in 2026Q1, reflecting a consistent liquidation of resources to fund ongoing clinical development in the absence of a self-sustaining commercial revenue stream.

The steady contraction of the asset base suggests that the company is consuming its capital reserves at a rate that outpaces its ability to replenish them through milestone payments. This trajectory indicates that the business model remains entirely dependent on external financing to maintain its current operational scale.

Cash Runway Nearing Critical Threshold

Based on the most recent quarterly data, the company's cash position has dwindled to $30.2M as of 2026Q1, a significant reduction from the $135.7M reported in 2023Q4, which highlights a precarious liquidity buffer relative to the company's high fixed R&D burn rate.

While the current ratio of 2.56 suggests a superficial level of short-term coverage, the absolute cash balance is insufficient to support extended Phase 2 clinical trials without further capital raises. Investors should monitor the cash burn closely, as the current liquidity profile leaves little room for operational delays or unexpected clinical setbacks.

Minimal Leverage Amidst Capital Constraints

According to historical balance sheet data, the company maintains a conservative debt-to-equity ratio of 0.14 as of 2026Q1, indicating that management has avoided significant debt financing, likely due to the lack of stable cash flows required to service interest obligations.

The reliance on equity rather than debt is a standard, albeit necessary, strategy for a clinical-stage biotech firm. However, the limited debt capacity suggests that the company lacks the flexibility to leverage its balance sheet for non-dilutive funding, further increasing the likelihood of future equity issuance.

Equity Quality Diluted by Losses

As evidenced by the cumulative retained earnings deficit of $665.2M in 2026Q1, the company's equity base has been severely eroded by years of operating losses, which underscores the significant value destruction inherent in the current clinical-stage business model.

The negative trend in retained earnings highlights the persistent challenge of funding high-cost R&D without a commercial product. This erosion of equity quality suggests that shareholders face ongoing dilution risk as the company continues to tap capital markets to offset its structural deficit.

Hidden Risks in Asset Composition

Based on reported figures, the company's asset mix is heavily weighted toward cash and minimal PPE, with zero goodwill, which suggests that the balance sheet is not distorted by intangible asset valuations but is instead highly sensitive to the rapid depletion of liquid capital.

The absence of goodwill is a positive indicator of accounting transparency, yet it also means there is no cushion of intangible value to support the company's valuation during periods of clinical failure. The primary risk remains the lack of tangible assets that could be monetized in a distress scenario.

ALGS — Frequently Asked Questions

Quick answers to the most common questions about buying ALGS stock.

What are the total assets of Aligos Therapeutics, Inc. (ALGS)?

As of 2025, Aligos Therapeutics, Inc. (ALGS) had total assets of $88.5M including $82.9M in current assets.

How much debt does Aligos Therapeutics, Inc. (ALGS) have?

Aligos Therapeutics, Inc. (ALGS) carries total debt of $5.3M, offset by $77.8M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Aligos Therapeutics, Inc.?

Aligos Therapeutics, Inc. (ALGS) has total shareholders' equity (book value) of $53.5M ($5.42 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Aligos Therapeutics, Inc.'s current ratio and liquidity?

Aligos Therapeutics, Inc. (ALGS) reported a current ratio of 3.90x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.